Pipeline

Discovery Hit to Lead Lead Optimisation IND Enabling Studies

Redx Oncology

Smoothened inhibitor
Smoothened inhibitor
Smoothened inhibitor

Redx is developing a best-in-class inhibitor designed to address basal cell carcinoma (BCC) through topical application. BCC is the most common form of skin cancer, with 2.8m cases per year diagnosed in the USA alone.

cFMS inhibitor
cFMS inhibitor
cFMS inhibitor

cFMS is expressed on monocyte/macrophage cells. Redx's small molecule inhibitors have the potential to treat cancer by modulating the tumour micro-environment and reducing bone metabolism to ameliorate fractures caused by cancer metastases. Potential treatment areas also include autoimmune diseases such as rheumatoid arthritis.

BTK inhibitor
BTK inhibitor
BTK inhibitor

Redx is developing best-in-class inhibitors of BTK for treatment of leukaemia, other blood cancers and autoimmune diseases such as rheumatoid arthritis, lupus and Sjögren's syndrome.

Porcupine inhibitor
Porcupine inhibitor
Porcupine inhibitor

Redx is developing novel inhibitors of Porcupine, a key component of the Wnt cancer stem cell pathway. Potential opportunities exist for the treatment of breast, pancreatic, head and neck cancers.

IDO inhibitor
IDO inhibitor
IDO inhibitor

Redx is developing novel inhibitors of IDO, a pathway active in many cancers. Potential treatment opportunities include solid tumours such as skin and lung cancers.

Pan-Raf inhibitor
Pan-Raf inhibitor
Pan-Raf inhibitor

Redx is developing novel small molecule therapeutics with combined activity against different Raf isoforms. These novel compounds target mechanisms of resistance associated with existing MAPK pathway inhibitors in conditions such as colorectal cancer.

Tumour Immunology Targets
Tumour Immunology Targets

Redx is working on a range of targets designed to activate the immune system to attack tumours. Potential therapeutic areas include multiple tumour types such as skin, lung and kidney cancers.

Redx Anti-Infectives

MDR Gram-positive
MDR Gram-positive
MDR Gram-positive

Drug resistant Gram-positive bacteria include streptococcus and staphylococcus. Redx is working in partnership with the NHS (The Royal Liverpool and Broadgreen University Hospital Trust) on new drugs to tackle drug-resistant bacteria, particularly MRSA.

MDR Gram-negative
MDR Gram-negative
MDR Gram-negative

Gram-negative bacteria include E. coli and Pseudomonas. Redx is developing antibiotics against multi-drug resistant Gram-negative bacteria, with the potential opportunities to treat urinary tract infections, pneumonia and intra-abdominal infections.

Hepatitis B
Hepatitis B

More than 350 million people worldwide are estimated to be chronically infected with HBV. Redx is developing small molecule immune modulators designed to treat and ultimately eradicate HBV infection.

Influenza
Influenza

Redx is developing inhibitors for the treatment and prophylaxis of infections caused by influenza A and B viruses, including drug-resistant strains.

Novel Bacterial Targets
Novel Bacterial Targets

Redx has several programmes at discovery stage focused on novel anti-bacterial targets.

Imm.

BTK inhibitor
BTK inhibitor
BTK inhibitor

Redx is developing best-in-class inhibitors of BTK for treatment of leukaemia, other blood cancers and autoimmune diseases such as rheumatoid arthritis, lupus and Sjögren's syndrome.

Discovery Hit to Lead Lead Optimisation IND Enabling Studies